Venture Capital Paint Point: The “Exit Valuation Gap”

The Problem: You have a promising asset, but have you de-risked its path all the way to reimbursement? A weak regulatory strategy or unclear commercial roadmap can create a massive valuation discount at exit.

Our Solution: Regulatory-to-Reimbursement Blueprint

• The Fix: We develop an integrated, end-to-end strategy from first-in-human trials to market access and outcomes-based contracting.
• VC Outcome: You maximize the asset’s attractiveness and valuation for strategic acquirers by proving a clear, de-risked path to revenue.

Price:  Starting from $55,000 USD.